Francesco Bianchi Sells 1,250 Shares of LivaNova PLC (NASDAQ:LIVN) Stock

LivaNova PLC (NASDAQ:LIVN) Director Francesco Bianchi sold 1,250 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the sale, the director now owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. The trade was a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

LivaNova Stock Performance

Shares of LIVN stock opened at $51.50 on Friday. The firm has a market capitalization of $2.80 billion, a price-to-earnings ratio of 122.62 and a beta of 0.98. The stock has a fifty day moving average of $51.97 and a 200 day moving average of $51.49. LivaNova PLC has a 52 week low of $43.15 and a 52 week high of $64.47. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on LIVN. Needham & Company LLC reissued a “buy” rating and issued a $75.00 target price on shares of LivaNova in a research note on Monday, November 25th. The Goldman Sachs Group initiated coverage on LivaNova in a research report on Friday, October 4th. They issued a “buy” rating and a $65.00 price objective for the company. StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 16th. Robert W. Baird upped their price target on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Finally, Mizuho cut their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $69.17.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in LIVN. Fifth Third Bancorp increased its position in shares of LivaNova by 97.1% during the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after buying an additional 332 shares during the period. Canada Pension Plan Investment Board bought a new stake in LivaNova during the 2nd quarter valued at approximately $88,000. Central Pacific Bank Trust Division purchased a new position in shares of LivaNova during the 3rd quarter worth approximately $178,000. TradeLink Capital LLC purchased a new position in shares of LivaNova during the 2nd quarter worth approximately $208,000. Finally, Captrust Financial Advisors purchased a new position in shares of LivaNova in the 3rd quarter valued at approximately $217,000. 97.64% of the stock is currently owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.